PRLD (Prelude Therapeutics) FCF Margin %: -473.47% (As of Mar. 2026)


PRLD Prelude Therapeutics Inc PRLD
26 GF Score
Price $4.99
! 6 Warning Signs
View Full Analysis

What is Prelude Therapeutics FCF Margin %?

Prelude Therapeutics PRLD +1.63% 26 FCF Margin % is -473.47% as of Mar. 2026. GuruFocus rates PRLD with a GF Score™ of 26/100. The stock has 6 warning signs investors should review. Among 949 Biotechnology companies, Prelude Therapeutics ranks worse than 63.33% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Prelude Therapeutics's Free Cash Flow for the three months ended in Mar. 2026 was $-21.69 Mil. Prelude Therapeutics's Revenue for the three months ended in Mar. 2026 was $4.58 Mil. Therefore, Prelude Therapeutics's FCF Margin % for the quarter that ended in Mar. 2026 was -473.47%.

As of today, Prelude Therapeutics's current FCF Yield % is -11.01%.

The historical rank and industry rank for Prelude Therapeutics's FCF Margin % or its related term are showing as below:

PRLD' s FCF Margin % Range Over the Past 10 Years
Min: -1480.74   Med: -972.53   Max: -261.82
Current: -261.82

During the past 8 years, the highest FCF Margin % of Prelude Therapeutics was -261.82%. The lowest was -1480.74%. And the median was -972.53%.

PRLD's FCF Margin % is ranked worse than
63.33% of 949 companies
in the Biotechnology industry
Industry Median: -82.65 vs PRLD: -261.82

Prelude Therapeutics FCF Margin % Related Terms

Prelude Therapeutics FCF Margin % Historical Data

* Premium members only.

The historical data trend for Prelude Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prelude Therapeutics FCF Margin % Chart

Prelude Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 -1,480.74 -464.32

Prelude Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -294.08 409.91 -473.47

PRLD vs DMAC, RCKT, CYDY: FCF Margin % Comparison

For the Biotechnology subindustry, Prelude Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Prelude Therapeutics FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Prelude Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Prelude Therapeutics's FCF Margin % falls into.


PRLD
26GF Score
Prelude Therapeutics Inc PRLD
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Prelude Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Prelude Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-56.369/12.14
=-464.32 %

Prelude Therapeutics's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-21.685/4.58
=-473.47 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -473.47% mean?
Prelude Therapeutics (PRLD) has a FCF Margin % of -473.47% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Prelude Therapeutics and its competitors. According to the industry distribution chart, Prelude Therapeutics ranks #601 out of 949 companies in the Biotechnology industry, placing it in the top 63.3%.
Is Prelude Therapeutics' FCF Margin % too high?
Prelude Therapeutics' current FCF Margin % is -473.47%. Based on the distribution chart, Prelude Therapeutics ranks #601 out of 949 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Prelude Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Prelude Therapeutics' FCF Margin % compare to DMAC and RCKT?
According to the Biotechnology industry distribution chart, Prelude Therapeutics ranks #601 out of 949 companies for FCF Margin %. This places Prelude Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Prelude Therapeutics and its competitors. Prelude Therapeutics's current FCF Margin % is -473.47%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prelude Therapeutics stock overvalued right now?
Prelude Therapeutics (PRLD) has a current FCF Margin % of -473.47%. The current FCF Margin % is -473.47%. Prelude Therapeutics' overall GF Score™ is 26/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Prelude Therapeutics (PRLD), the current FCF Margin % is -473.47% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Prelude Therapeutics Business Description

Address 175 Innovation Boulevard, Wilmington, DE, USA, 19805
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.
26GF Score

Get the complete analysis for PRLD

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.99
Price